Written by James Peterson.
In a development that has raised eyebrows across the nation, Moderna has announced a new lineup of mRNA vaccines aimed at combating diseases purportedly triggered by their own COVID-19 jabs. With the Biden administration’s FDA poised to rubber-stamp Moderna’s latest offering, including a respiratory syncytial virus (RSV) vaccine, concerns are mounting about the safety and efficacy of this technology and the potential conflicts of interest at play.
A Troubling Trend
The announcement heralds the advancement of vaccines targeting Epstein-Barr virus (EBV), Varicella-zoster virus (VZV), and Norovirus into late-stage development, marking a significant push by Moderna to expand its mRNA vaccine portfolio. This comes amidst widespread reports of adverse reactions to the COVID-19 mRNA vaccines, including severe and sometimes fatal health issues.
Critics argue that Moderna’s move to address vaccine-induced diseases could represent a disturbing cycle of problem-reaction-solution, where the pharmaceutical giant profits from both the cause and the cure. The ethical implications of such a scenario are profound, raising questions about the long-term consequences of relying on mRNA technology for disease prevention and treatment.
The Science Behind the Concern
Experts like Brian Hooker, Ph.D., and others have detailed how mRNA vaccines can suppress the body’s innate immunity, potentially leading to the reactivation of latent viruses and the emergence of new infections. This suppression of critical immune functions could explain the alarming rate of diseases like shingles following COVID-19 vaccination.
Moreover, the push for mRNA solutions for a range of conditions from cardiovascular disease to cancer raises the specter of unforeseen side effects and the possible exacerbation of the very ailments they aim to prevent.
Our Take
The Biden administration’s tacit approval of Moderna’s expanding mRNA vaccine agenda underscores a troubling disregard for the principle of “first, do no harm.” With the FDA seemingly in lockstep with Big Pharma’s ambitions, the American public is left to navigate a healthcare landscape where the lines between treatment and business interests are increasingly blurred.
As we witness an unprecedented push for new vaccines and therapeutic interventions, the need for transparency, rigorous scientific scrutiny, and ethical consideration has never been more acute. The potential for mRNA technology to revolutionize medicine cannot be denied, but neither can the risks it poses if deployed without due caution and respect for patient safety.
In this brave new world of biotechnology, we must remain vigilant, questioning the motives behind the rush to market and the long-term impact on public health. The promise of innovation should not blind us to the lessons of the past, nor should it allow profit motives to override the Hippocratic oath. As guardians of our own health and that of future generations, we must demand accountability, integrity, and the unwavering commitment to doing no harm.
